Charming Medical Ltd is facing a significant setback as trading in its securities on Nasdaq has been suspended following a delisting determination. The company, which specializes in Traditional Chinese Medicine (TCM)-inspired therapies, did not request a hearing to appeal the decision, leading to the immediate suspension effective November 9, 2026.

The delisting determination was communicated to Charming Medical in a letter dated October 29, 2026, from Nasdaq’s Listing Qualifications Staff. The company was notified that it would be delisted under Nasdaq Listing Rule IM-5101-4, which allows for delisting based on potential misconduct affecting a company’s securities.

Charming Medical, which trades under the ticker MCTA on Nasdaq, did not take action to contest the delisting by the November 5 deadline. As a result, trading in the company’s securities will be suspended at the opening of business on November 9, 2026. Nasdaq will subsequently file a Form 25-NSE with the U.S. Securities and Exchange Commission (SEC) to remove the company’s securities from listing and registration.

In a press release issued on the same day, Charming Medical confirmed the suspension and noted that the delisting does not have an immediate impact on its ongoing business operations or financial condition. The company continues to operate its wellness centers in Hong Kong, offering a range of TCM-inspired services and products.

The company previously faced regulatory scrutiny when the SEC temporarily suspended trading in its securities from November 12 to November 25, 2025, due to concerns of potential market manipulation. This suspension was linked to recommendations made by unknown individuals on social media, which appeared to artificially inflate the price and trading volume of the company's securities.

Under Nasdaq Listing Rule 5101, the exchange has broad authority to maintain the quality and public confidence in its market, which includes preventing fraudulent and manipulative acts. The rule allows Nasdaq to delist companies based on potential misconduct, even if the company itself has not been found to have engaged in wrongdoing.

Following the suspension of trading on Nasdaq, Charming Medical's securities may be eligible for quotation in the over-the-counter (OTC) market. However, there is no assurance that any broker-dealer will quote the company’s securities, which could lead to limited availability of information and increased volatility.

Charming Medical Ltd, headquartered in Hong Kong, integrates TCM principles with modern technology to enhance quality of life and promote holistic well-being. The company operates wellness centers providing services such as womb-warming therapy and pelvic detox therapy, and also develops TCM-inspired supplements and beauty products under its “Beauty Lab” brand.

The future remains uncertain for Charming Medical as it navigates this regulatory hurdle. The company has indicated that it will continue to conduct its business in the ordinary course and will make further announcements as necessary.

As the health services sector continues to evolve, this incident serves as a reminder of the regulatory challenges that companies may face, particularly those in emerging markets and industries.